: High-dose (500 mg orally four times daily) vancomycin is considered by many investigators to be the most effective treatment for antibiotic-associated Clostridium difficile colitis. However, a lower dosage of 125 or 150 mg given three of four times a day has become popular, has been shown to be effective, and is less expensive than the high-dose regimen. We therefore decided to compare two vancomycin dosage regimens in a randomized trial.: The study involved 46 hospitalized patients with serious underlying diseases complicated by C. difficile diarrhea or colitis. Patients were assgined (according to a table of random numbers) to treatment with either 125 or 500 mg of vancomysin orally four times daily for an average of 10 days.: No signif...
Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomyc...
Clostridium difficile has been historically viewed as a hospital acquired infection. However, the em...
• Clostridium difficile infection (CDI) is the main cause of antibiotic-associated pseudomembranous ...
Current therapy of Clostridium difficile diarrhea (CDD) is problematic. Optimal treatment for CDD re...
Sixty-five patients were treated with oral vancomycin for Clostridium difficile colitis associated w...
BACKGROUND: For severe, complicated Clostridium difficile infection (CDI), concomitant treatment wit...
Abstract Background Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium d...
Background: Clostridium difficile cause serious diarrheal disease with potentially fatal complicati...
A critical appraisal and clinical application of Johnson S, Louie TJ, Gerding DN, et al. Vancomycin,...
(See the IDSA lecture by Bartlett on pages 1489–92) The epidemiology, clinical severity, and case-fa...
treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. CID 2007;45:...
Class of 2012 AbstractSpecific Aims: The incidence of non-response, recurrence, relapse, and rate of...
BACKGROUND Infection with Clostridium difficile is the primary infective cause of antibiotic-asso...
Purpose: The most recent published guidelines on Clostridium difficile–associated diarrhea (CDAD) de...
Clostridium difficile infection (CDI) continues to possess a significant disease burden in the Unite...
Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomyc...
Clostridium difficile has been historically viewed as a hospital acquired infection. However, the em...
• Clostridium difficile infection (CDI) is the main cause of antibiotic-associated pseudomembranous ...
Current therapy of Clostridium difficile diarrhea (CDD) is problematic. Optimal treatment for CDD re...
Sixty-five patients were treated with oral vancomycin for Clostridium difficile colitis associated w...
BACKGROUND: For severe, complicated Clostridium difficile infection (CDI), concomitant treatment wit...
Abstract Background Oral vancomycin (125 mg qid) is recommended as treatment of severe Clostridium d...
Background: Clostridium difficile cause serious diarrheal disease with potentially fatal complicati...
A critical appraisal and clinical application of Johnson S, Louie TJ, Gerding DN, et al. Vancomycin,...
(See the IDSA lecture by Bartlett on pages 1489–92) The epidemiology, clinical severity, and case-fa...
treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. CID 2007;45:...
Class of 2012 AbstractSpecific Aims: The incidence of non-response, recurrence, relapse, and rate of...
BACKGROUND Infection with Clostridium difficile is the primary infective cause of antibiotic-asso...
Purpose: The most recent published guidelines on Clostridium difficile–associated diarrhea (CDAD) de...
Clostridium difficile infection (CDI) continues to possess a significant disease burden in the Unite...
Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomyc...
Clostridium difficile has been historically viewed as a hospital acquired infection. However, the em...
• Clostridium difficile infection (CDI) is the main cause of antibiotic-associated pseudomembranous ...